Novartis gets Menveo vaccine approval

The FDA has approved Novartis' Menveo vaccine for use in 11-55 year olds to help protect against meningitis and sepsis caused by four common vaccine-preventable serogroups. That approval could help Novartis rake in up to $650 million a year.

"Even with early and appropriate treatment, patients can die from meningococcal disease, often within 24-48 hours of onset of symptoms. Menveo achieved a higher immune response than the other currently available vaccine, which is very reassuring," Keith Reisinger, MD, medical director at Primary Physicians Research, says in a statement.

Menveo was originally slated for approval in 2009, but the FDA asked Novartis for more information on the meningitis vaccine's production. Fortunately for Novartis, it did not need to conduct more clinical trials. The company hopes to further expand the vaccine's indication to infants and children aged between 2 and 10 years.

- here's Novartis' release
- see the Reuters report for more

ALSO: The FDA has granted Novartis' oral multiple sclerosis development compound Gilenia (FTY720) priority review status. Report

Suggested Articles

Insitro picked up $143 million to build out its technology, pursue new targets and advance treatments for genetically defined patient groups.

Generation Bio filed for a $215 million IPO to advance a pair of gene therapies for liver disease and push one of them into the clinic.

The IPO will push Avidity's lead muscle disorder program through IND-enabling studies and into the clinic in 2021.